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Abstract:  
Histone deacetylases (HDACs) are enzymes, which catalyze the removal of acetyl moiety from acetyl-lysine within the histone 
proteins and promote gene repression and silencing resulting in several types of cancer. HDACs are important therapeutic targets 
for the treatment of cancer and related diseases. Hydroxamic acid inhibitors show promising results in clinical trials against 
carcinogenesis. 120 hydroxamic acid derivatives were designed as inhibitors based on hydrophobic pocket and the Zn (II) catalytic 
site of HDAC8 active site using Structure Based Drug Design (SBDD) approach. High Throughput Virtual screening (HTVs) was 
used to filter the effective inhibitors. Induced Fit Docking (IFD) studies were carried out for the screening of eight inhibitors using 
Glide software. Hydrogen bond, hydrophobic interactions and octahedral coordination geometry with Zn (II) were observed in the 
IFD complexes.  Prime MM-GBSA calculation was carried out for the binding free energy, to observe the stability of docked 
complexes. The Lipinski’s rule of five was analyzed for ADME/Tox drug likeliness using Qikprop simulation. These inhibitors 
have good inhibitory properties as they have favorable docking score, energy, emodel, hydrogen bond and hydrophobic 
interactions, binding free energy and ADME/Tox. However, one compound (Cmp22) successively satisfied all the studies among 
the eight compounds screened and seems to be a promising potent inhibitor against HDAC8. 
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Background: 
Histones are small basic proteins with two domains. The C-
terminal domain is located inside the nucleosome core and the 
N-terminal domain is rich in lysine residues extending out of 
the nucleosome core [1]. Positive charge of the lysine residues 
makes the histones to bind with the negatively charged DNA 
that mainly regulates the interactions between DNA and 
histones. A single nucleosomal unit consists of octameric 
histones (H3–H4 tetramer and H2A–H2B dimer) coiled by a 
stretch of 146 base pairs of DNA. Among the above four 
histones, H3 and H4 are mainly targeted for various post-
translational modifications including acetylation, 
phosphorylation, and methylation [1, 2]. Among such 
modifications, in particular, acetylation has been highlighted as 
an important mechanism in post-transcriptional determination 
[2, 3].  Acetylation of the histones can be controlled by two 
counteracting enzymes in the form of antagonist such as 
Histone acetyl transferases (HATs) and HDACs. Addition and 
removal of acetyl moieties were catalyzed from the ε -amino 
groups of lysines [4-6]. HDACs are important gene expression 
regulators in eukaryotic cells affecting angiogenesis, cell-cycle 
arrest, apoptosis, terminal differentiation of different cell types 
[7, 8]. Phylogenic analyses reveal human HDACs into four 
distinct classes, Class I-IV. Class I includes HDACs 1-3 and 8 
that are homologous to yeast Rpd3 (exclusively expressed in the 
nucleus). Class II includes HDACs 4-7, 9 and 10 that are 
homologous to yeast Hda1 (shuttled between the cytoplasm 
and the nucleus). Class III includes Sirtuins 1-7 that are BIOINFORMATION  open access 
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homologous to yeast sir2. Class IV, the recently identified one 
includes HDAC 11. Class III HDACs are structurally unrelated 
to the other three classes of HDACs and Class IV HDACs 
possess structural homology and has only a low overall 
sequence similarity with both classes I and II. HDACs 1-11 are 
metalloenzymes that require Zn (II) at catalytic site for 
deacetylation mechanism. HDACs in classes I and IV are 42-45 
kDa, whereas class II HDACs are about 120-130 kDa in size [9-
11]. The malignancy of leukemias and lymphomas are linked to 
the aberrant recruitment of HDACs [12, 13]. The HDAC 
inhibitors (HDACIs) are reported to have anti-tumor activity in 
preclinical models and in clinical trials, promisingly to become 
new antineoplastic drugs [14]. HDACIs are shown to alter gene 
transcription and exert various anti-tumor effects [11, 15, 16]. 
HDAC8 protects the human ever-shorter telomerase 1b protein, 
a telomerase activator from ubiquitin-mediated degradation 
[13], associates with R-actin cytoskeleton and plays a vital role 
in the regulation of contractility in differentiating smooth 
muscle cells [14]. Recent studies indicate that HDAC8 inhibitor 
induces apoptosis in T cell derived tumor cells but not 
increasing the histone or tubulin acetylation levels [11]. 
Suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor 
has been clinically validated and approved by Food and Drugs 
Administration in the treatment of cutaneous T cell lymphoma 
as a new therapeutic drug [17]. In the recent computational 
studies  [18-21], it was observed that the known HDAC 
inhibitors and newly designed HDAC8 inhibitors docked at the 
active site of HDAC8 are showing the potent results. These 
results could be used to synthesize the HDAC8 inhibitors or 
suggesting designing some novel inhibitors against HDAC8 in 
further studies. Our current study aims to use the SBDD 
approach for designing new compounds which are structurally 
related to SAHA inhibitor. Simultaneously, HTVs, IFD and 
Prime MM-GBSA studies were also carried out. Then, hydrogen 
and hydrophobic interaction studies were analyzed in the 
docked complexes. The results of in silico and interactions 
studies of SBDD complexes were compared with that of in silico 
results of SAHA to show the inhibitory potency of the designed 
inhibitors. These comparisons suggest that the designed SAHA 
like compounds can be used as HDACIs against carcinogenesis 
in future. The designed HDACIs may be potent in the in vitro 
and in vivo studies.  
 
Methodology: 
All the molecular modeling calculations like rigid (HTVs) and 
flexible (IFD) docking, binding free energy calculation, and 
ADME/Tox were carried out using Glide software (Schrödinger 
LLC 2009, USA) in CentOS EL-5 workstation. PyMOL software 
was used for graphical visualization, analysis of the hydrogen 
bond interactions and Zn (II) coordination geometry to produce 
quality images. Hydrophobic interactions were observed 
between the active site of target and ligand using Ligplot 
software [22]. 
 
Protein Preparation: 
The X-ray crystal structure of human HDAC8 complexed with 
SAHA (1T69) was recovered from Protein Data Bank (PDB: 
www.rcsb.org). The deposited structure of PDB was modified 
viz addition of hydrogen atoms, assigning correct bond orders, 
fixing of the charges and orientation of groups for Glide 
modeling calculations. The orientation of hydroxyl groups and 
amide groups of ASN, GLN and HIS were converted into the 
charged state. The amino acid flips were assigned and H-bonds 
optimized iteratively. Non-hydrogen atoms were energy 
minimized until the average root mean square deviation 
reaches 0.3Å. Schrödinger modules Glide, Prime, QSite, Liasion 
and MacroModel were used for protein preparation.  
 
Structure Based Drug Design and Ligand Preparation: 
SBDD has the potential significance in pharmaceutical related 
researches, especially in the new drug design progress [23-24]. 
Application of SBDD techniques is supported by an exponential 
growth in the number of experimental protein 3D structures 
from X-ray crystallography or NMR spectroscopy [23, 25]. The 
HDAC8 active site consists of a long, narrow and primarily 
hydrophobic tunnel formed by G151, F152, H180, F208, M274, 
and Y306. The end of the hydrophobic tunnel contains a 
catalytic site [26].  Designing a series of 120 hydroxamic acid 
derivatives (data not shown) based on the active site residues 
and the catalytic Zn (II) using SBDD approach has been carried 
out for the molecular modeling studies. The basic core of the 
molecules is similar to SAHA inhibitor. Designed inhibitors 
were subjected into ligand preparation by Ligprep 2.3 module 
(Schrödinger). Ligprep performs addition of hydrogens, 2D to 
3D conversion, realistic bond lengths and bond angles, low 
energy structure with correct chiralities, ionization states, 
tautomers, stereochemistries and ring conformation.  
 
High Throughput Virtual screening:  
HTVs is one of the methods to screen one or more compounds 
from a set of compounds. Glide performs HTVs that requires 
previously calculated receptor grid and one or more ligand 
structures. The active site of the receptor and its properties were 
calculated on a grid that provides accurate scoring function 
along with energy when ligand is docked. The receptor grid 
allows the ligands to bind in more than one possible and 
meaningful conformation. During the receptor grid generation 
process, the minimized crystal structure bound with SAHA was 
loaded in the workspace; the active site of the receptor was 
calculated automatically and shown as a grid box by picking 
the ligand. In HTVs, the flexibility of the receptor is restricted, 
but van der Waals radii of non-polar atoms were calculated to 
decrease close contact penalties between ligand and active site 
residues. All the designed compounds were screened against 
the calculated grid box using Standard Precision (SP) docking 
and 30 best compounds were selected based on the Docking 
score, Glide energy, Glide emodel and non-bonded interactions. 
The selected compounds were subjected to Extra Precision (XP) 
docking, which is a more powerful scoring and discriminating 
procedure, where the receptor was held rigid while docking. XP 
docking took more time for screening compared to SP docking. 
Eight compounds (Figure 1) were chosen by the above selection 
method to proceed with IFD.   
 
Induced Fit Docking: 
In SP and XP docking studies, ligands were docked at the active 
site of a receptor, where the receptor was held rigid and the 
ligands were free to rotate. However, rigid receptor with 
flexible ligand may provide misleading results in docking 
simulation. When ligand binds at the active site, it undergoes 
side-chain or backbone conformation or both in many proteins. 
These conformational changes allow the receptor to generate 
close conforms to the shape and binding mode of the ligand. 
This is known as IFD. IFD is one of the main complicating BIOINFORMATION  open access 
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factors in SBDD studies and predicts accurate ligand binding 
modes and concomitant structural movements in the receptor 
using modules of Glide and Prime. Python scripts automate the 
IFD process and an interface in Maestro (Schrödinger). Energy 
minimized human HDAC8 protein complexed with SAHA was 
loaded in the workspace and the ligand was selected to specify 
the active site.  Then, the IFD calculations were carried out for 
eight compounds (from SP and XP screening). Van der Waals 
radii of non-polar atoms of the receptor and ligand were scaled 
by a factor of 0.50, and 20 conformational poses were calculated. 
Based on the docking score, Glide energy, Glide emodel and 
non bonded interactions noticed in IFD results, the best 
conformation was chosen for further calculations. 
 
 
Figure 1: Chemical diagrams of hydroxamic acid derivatives 
used in the study. (i) N1-hydroxy-N8-phenyloctanediamide 
[SAHA], (ii) N1-(7-(9H-carbazol-4-yl)-1H-indol-3-yl)-N8-
hydroxyoctanediamide [Cmp14], (iii) N1-(4-(9H-carbazol-1-yl)-
1H-indol-3-yl)-N8-hydroxyoctanediamide [Cmp17], (iv) N1-(6-
(9H-carbazol-3-yl)-1H-indol-3-yl)-N8-hydroxyoctanediamide 
[Cmp22], (v) N1-(6-(2-amino-2-formylethyl)-1H-indol-3-yl)-N8-
hydroxyoctanediamide [Cmp36], (vi) N1-hydroxy-N8-(5-
phenyl-1H-indol-3-yl) octanediamide [Cmp52], (vii) 3-(N1-
hydroxyoctanediamido)-1H-indole-6-carbonyl chloride 
[Cmp108], (viii) N1-(5-formyl-1H-indol-3-yl)-N8-
hydroxyoctanediamide [Cmp118], (ix) N1-(6-formyl-1H-indol-
3-yl)-N8-hydroxyoctanediamide [Cmp119]. 
 
Prime MM-GBSA: 
Prime MM-GBSA approach was used to calculate ligand 
binding energies and ligand strain energies for a ligand and a 
single receptor. MM-GBSA is a method that combines OPLS-
AA molecular mechanics energies (EMM), an SGB solvation 
model for polar solvation (GSGB), and a non-polar solvation 
term (GNP) composed of the non-polar solvent accessible 
surface area and van der Waals interactions. Here, the IFD pose 
viewer file of the best conformation chosen was given as the 
source in Prime MM-GBSA simulation. The total free energy of 
binding: ∆Gbind = Gcomplex – ( Gprotein + Gligand ), where G 
= EMM + GSGB + GNP 
 
ADME/Tox: 
QikProp, the prediction program designed by Prof. William L. 
Jorgensen was used to calculate ADME (Absorption, 
Distribution, Metabolism, and Excretion) properties. Qikprop is 
quick, accurate and predicts physically significant descriptors 
and pharmaceutically relevant properties of organic molecules. 
Ligprep minimized ligands were given as a source in Qikprop 
3.2. Qikprop modules provide the ranges of molecular 
predicting properties for comparing the properties of a 
particular molecule with those of 95% of known drugs 
(Schrödinger 2009). 
 
Discussion: 
SAHA was redocked at the active site of the target. The docked 
complex has a docking score of -2.37, glide energy -44.79 and 
glide emodel -50.16 (Table 1 see supplementary material). The 
ligand maintains four hydrogen bond interactions with the 
active site residues, namely, D178 (OD2), H143 (ND1), H180 
(NE2) and Y306 (OH) (Table 2 see supplementary material). 
The Zn (II) ion holds six coordination interactions with the 
catalytic site residues. In the octahedral geometry formed, it 
maintains four interactions with the active site residues and two 
interactions with O1 and O2 atoms of SAHA. The coordination 
distance range is 2.04-2.47 Å (Table 3 see supplementary 
material). SAHA has hydrophobic interactions with G151, F207, 
and F208 residues at the active site (Table 4 see supplementary 
material). Compound (Cmp) 14 docked complex orientation 
possesses good docking score -6.25, glide energy -62.69 and 
glide emodel -87.81 (Table 1). Cmp14 maintained three 
hydrogen bond interactions with D178 (OD2), H180 (NE2) and 
Y306 (OH). In addition, two hydrogen bond interactions were 
observed with G140 (O) and Q263 (NE2) residues (Table 2). Zn 
(II) ion forms octahedral coordination with certain amino acid 
residues and the ligand. Five coordination interactions were 
formed with the active site residues and one interaction with O2 
of the Cmp14. The coordination distance range is 2.01Å-2.37Å 
(Table 3). Six hydrophobic interactions were noticed in the 
complex viz. H143, F152, C153, F207, F208 and M274 (Table 4).  
 
Cmp 17 docked at the active site of target has good docking 
score -6.64, glide energy -55.09 and glide emodel -76.13 (Table 
1). Interestingly, the ligand has seven hydrogen bond 
interactions with active site residues H143 (NE2), D178 (OD2), 
G206 (O), F208 (N), D267 (OD2), G303 (O) and Y306 (OH) 
(Table 2). Zn (II) ion forms octahedral coordination geometry 
with the catalytic site residues and the ligand. The ligand atoms 
O2 and O3 retained two coordinations with Zn (II) ion and 
active site residues have four, all in the distance range 2.07-
2.49Å  (Table 3). Cmp17 maintains four hydrophobic 
interactions with G151, F152, H180, and M274 residues at the 
tunnel-shaped hydrophobic region (Table 4). For Cmp 22, 
docking score is -7.00, glide energy is -67.02 and glide emodel is 
-95.72  (Table 1). The ligand exhibits five hydrogen bond 
interactions, three interactions with H180 (NE2), G206 (O) and BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 7(3): 134-141 (2011)  137             © 2011 Biomedical Informatics
 
G303 (O) and remaining two hydrogen bonds with Y306 (OH) 
(Table 2 & Figure 2a). Zn (II) ion is in octahedral coordination, 
five with active site residues and remaining one with the ligand. 
Zn (II) coordination distances range is in the range 2.00-2.38Å 
(Table 3 & Figure 2b). H143, G151, F152, F207, and F208 have 
hydrophobic interactions with the ligand at the active site 
(Table 4). Cmp 36 docked complex has a docking score of -6.38, 
glide energy of -61.09 and glide emodel of -82.68 (Table 1). The 
ligand has nine hydrogen bond interactions with G140 (O), 
D178 (OD2), H180 (NE2), K202 (NZ), G206 (O), Q263 (NE2), 
M274 (O), S276 (OG) and Y306 (OH) residues (Table 2). Zn (II) 
ion forms five coordinations with active site residues and one 
with the ligand. Octahedral coordination is observed and 
distances range is 2.01-2.30 Å (Table 3). The ligand is involved 
in five hydrophobic interactions with H143, G151, F152, F207 
and F208 (Table 4). For Cmp 52, five hydrogen bond 
interactions with active site residues Y100 (OH), G140 (O), D178 
(OD2), G206 (O) and Q263 (NE2) (Table 2) are observed. Ligand 
has favorable docking score of -5.93, glide energy of -56.54, and 
glide emodel of -76.55 (Table 1). Zn (II) ion maintains 
octahedral coordination geometry, one with the ligand and 
remaining five with active site residues. Coordination distance 
range is 2.06-2.42 Å (Table 3). This ligand has hydrophobic 
interactions with H143, G151, F152, F208 and M274 residues 
(Table 4).  
 
 
Figure 2: a) Hydrogen bond interactions of Cmp22 with active 
site residues; b) Octahedral coordination geometry of Cmp22 
with the catalytic site residues. 
 
Cmp 108 docked complex has a docking score -6.25, glide 
energy -53.99, and glide emodel -83.37 (Table 1). The ligand has 
six hydrogen bond interactions with the active site residues 
G140 (O) (two donors), D178 (OD2), H180 (NE2), Q263 (NE2) 
and Y306 (OH) (Table 2). The ligand has only one co-ordination 
and the active site residues have five coordinations with Zn (II) 
ion. The octahedral coordination distances range is 2.01-2.30 Å 
(Table 3). H143, G151, H180, F273, M274 residues have 
hydrophobic interactions with the ligand (Table 4). Cmp 118 
docked at the active site shows a docking score -6.25, glide 
energy -62.69, and  glide emodel -87.81 (Table 1). Four 
hydrogen bond interactions of the ligand were noted with the 
active site residues K33 (O), G140 (O), D178 (OD2), and Y306 
(OH) (Table 2). Zn (II) ion forms octahedral coordination with 
active site residues and ligand. The distance range is 2.00-3.25 Å 
(Table 3). Seven hydrophobic interactions are found with H143, 
G151, F152, C153, F208, M274 and Y306. Y306 has a hydrogen 
bond interaction with O3 of the ligand, coordination formed 
with Zn (II) ion and hydrophobic interactions with some of 
atoms in ligand (Table 4).   
Cmp 119-bound complex has a docking score -7.33, glide 
energy -57.90 and glide emodel -87.49 (Table 1). The active site 
residues H142 (NE2), D178 (OD2), H180 (NE2) (two donors), 
K202 (NZ), G206 (O), D267 (OD2) and Y306 (OH) have a total of 
eight hydrogen bond interactions with ligand (Table 2). In the 
octahedral coordination of the amino acids and ligand atoms 
with Zn (II) the distance range is 1.99-3.23 Å (Table 3). H143, 
G151, F152, F207, F208 and M274 residues show six 
hydrophobic interactions with the ligand (Table 4).  
 
Prime MM-GBSA and ADME/Tox:  
Prime MM-GBSA calculation was carried out for SAHA as well 
as for the eight compounds designed by SBDD approach. 
SAHA has the binding free energy (ΔG) of -42.28, which is 
compared with SBDD compounds. Cmp14, 22, 52, and 108 
showed good binding free energy (ΔG) -65.40, -66.66, -65.40, 
and -65.98, respectively. Cmp17, 36, 118 and 119 also have 
favorable binding energies of -45.69, -58.63, -54.93, and -59.77, 
respectively. All the above compounds have promising free 
energy calculated in the HDAC8 docked complexes (Table 4). 
Using the compounds designed by SBDD, the physiochemical 
properties were calculated in Qikprop simulation. All the 
compounds obey the Lipinski’s rules: molecular weight below 
500 Da, hydrogen bond donor (less than five except for Cmp36) 
and acceptor (less than ten). QPlogPo/w (octanol/water 
partition coefficient) for all the compounds is less than five. 
Cmp36 alone is violating (Table 4). Total solvent accessible 
surface area (SASA), hydrophobic component of the SASA 
(FOSA) and hydrophilic component of the SASA (FISA) were 
analyzed for the compounds that were abiding the ranges in 
Qikprop physiochemical properties. Qualitative human oral 
absorption was predicted. Cmp14, 17, 22, and 52 have high oral 
absorption (score: 3). Cmp108, 118, and 119 have medium oral 
absorption (score: 2). However, Cmp36 alone has low oral 
absorption (score: 1). Polar nitrogen and oxygen van der Waals 
surface area (PSA) of SBDD compounds were fulfilling the limit 
in physicochemical calculation (Table 4). All the compounds 
satisfy the values of partition coefficient of octanol/gas 
(QPlogPoct), water/gas (QPlogPw) and brain/blood 
(QPlogBB). Aqueous solubility (QPlogS) and skin permeability 
(QPlogKp) predicted for ligands lie in the allowed the solubility 
and permeability range (Table 4). 
 
Conclusion: 
In this study, 120 hydroxamic acid derivative inhibitors 
designed using SBDD approach were screened and eight 
compounds were taken against HDAC8 for the docking studies. 
These results were compared with SAHA using docking 
studies, hydrogen bond and hydrophobic interactions, binding 
free energy and physicochemical properties of ADME/Tox.   
Cmp22 and 119 have good docking score in IFD. Glide energy 
and emodel calculations showed that Cmp17 and Cmp22 have 
good values. Remaining SBDD compounds showed favorable 
docking score, glide energy and emodel. SBDD docked 
complexes showed good stability from energy calculations. 
Hydrogen bond interactions were analyzed for SBDD 
compounds that have favorable interactions with active site 
residues. Cmp36 has nine hydrogen bond interactions at the 
active site residues. However, the D…A distance range is 2.78-
2.97 Å for all the hydrogen bonds in Cmp22 with the active site 
residues and rest of the compounds possess some of the 
hydrogen bonds with distances more than 3.00 Å. G151, F152, BIOINFORMATION  open access 
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H180, F208, M274 and Y306 residues were primarily 
hydrophobic and form a tunnel shape at the active site of 
HDAC8 [26]. IFD reveals that G151, F152, H180, F208, M274 and 
Y306 residues have hydrophobic interactions. Octahedral 
coordination is formed with Zn (II) ion in all the complexes. 
Binding free energy calculation has favorable scores in the 
SBDD complexes. However, Cmp22 has good free energy value 
among all the complexes. In physicochemical properties, 
Cmp14, 17, 22, 52, 108, 118 and 119 abide the Lipinski’s rule of 
five and human oral absorption. All the compounds satisfied 
surface area calculations of SASA, FOSA, FISA, PSA and 
partition coefficient of QPlogPoct, QplogPw and QplogBB. All 
the SBDD compounds (except Cmp36) have a potent inhibitory 
property. Cmp22 satisfies all the in silico criteria like docking 
score, glide energy, glide emodel, free energy score, 
ADME/Tox, hydrogen bond and hydrophobic interactions. All 
SBDD compounds are favorable against HDAC8 and Cmp22 is 
found to be more potent among them, suggesting that 
inhibition of HDAC8 by Cmp22 could be revealed through in 
vivo and in vitro studies so that it could be used against various 
cancer therapies. 
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Supplementary material: 
 
Table 1: Induced fit docking score, glide energy and glide emodel calculations 
Compounds  Docking score  Glide energy (kcal/mol)  Glide emodel (kcal/mol) 
SAHA  -2.37  -44.79  -50.16 
Cmp14  -6.25  -62.69  -87.81 
Cmp17  -6.64  -55.09  -76.13 
Cmp22  -7.00  -67.02  -95.72 
Cmp36  -6.38  -61.09  -82.68 
Cmp52  -5.93  -56.54  -76.55 
Cmp108  -6.25  -53.99  -83.37 
Cmp118  -6.25  -62.69  -87.81 
Cmp119  -7.33  -57.90  -87.49 
Docking Score = a * vdW + b * Coul + Lipo + Hbond +Metal + BuryP + RotB + Site 
where, vdW-van der Waal energy; Coul - Coulomb energy; Lipo - lipophilic contact term;  HBond - hydrogen-bonding term; Metal 
- metal-binding term; BuryP - penalty for buried polar groups; RotB -penalty for freezing rotatable bonds; Site - polar interactions 
at the active site; and the coefficients of vdW and Coul are: a =0.065, b = 0.130. Glide energy is combination of the posed ligand and 
receptor. Glide Emodel is a specific combination of Docking Score , CvdW (CvdW = Coul + vdW is the non-bonded interaction 
energy between the ligand and the receptor) and the internal torsional energy of the ligand conformer. 
 
Table 2: Hydrogen bond interactions between HDAC8 active site residues and SBDD compounds along with SAHA 
Ligand Ligand 
atom 
Residues 
atom 
Distance(D…A) 
(Å) 
Ligand  Ligand 
atom 
Residues 
atom 
Distance(D…A) 
(Å) 
SAHA  O1  His 143 ND1  3.46  Cmp52  O1  Gly 140 O  2.77 
 O1  Asp  178  OD2  2.97    O1  Asp 178 OD2  3.57 
  O2  Tyr 306 OH  3.43    O1  Gln 263 NE2  3.46 
  O3  His 180  NE2  3.15    N1  Tyr 100 OH  3.31 
Cmp14  O1  His 180  NE2  2.78    N3  Gly 206 O  2.85 
  O2  Tyr 306 OH  3.06  Cmp108  O1  His 180  NE2  2.86 
  O3  Gly 140 O  2.86    O2  Gly 140 O  2.99 
  O3  Asp 178 OD2  3.55    O2  Asp 178 OD2  3.22 
 O3  Gln  263  NE2  3.49    O2  Gln 263 NE2  3.01 
Cmp17  O1  Phe 208 N  3.04    O3  Tyr 306 OH  2.90 
  O2  His 143 ND1  2.89    N3  Gly 140 O  3.09 
 O3  Asp  178  OD2  2.72  Cmp118  O2  Gly 140 O  2.89 
  O3  Asp 267 OD2  3.35    O2  Asp178 OD2  3.50 
  O3  Gly 303 O  2.80    O3  Tyr 306 OH  3.07 
  N1  Gly 206 O  2.94    N1  Lys 33 O  2.95 
  N4  Tyr 306 OH  2.75  Cmp119  O1  His 180  NE2  2.86 
Cmp22  O1  His 180  NE2  2.78    O2  Asp 178 OD2  3.22 
  O2  Tyr 306 OH  2.82    O2  His 180  NE2  3.34 
  O3  Gly 303 O  2.81    O2  Asp 267 OD2  2.97 
  O3  Tyr 306 OH  2.97    O2  Tyr 306 OH  2.82 
  N1  Gly 206 O  2.90    O4  Lys 202 NZ  2.95 
Cmp36  O1  Gly 140 O  2.89    N1  Gly 206 O  2.90 
 O1  Asp  178  OD2  3.54         
 O1  Gln  263  NE2  3.53         
  O2  Tyr 306 OH  2.81         
  O3  His 180  NE2  3.04         
 O4  Lys  202NZ  2.88         
  N3  Gly 206 O  2.91         
 N4  Met  274  O  3.11         
  N4  Ser 276 OG  3.19         
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Table 3: Coordination distance between coordinating residues/atoms with Zn ion 
Ligand Ion Residues/atoms Distance(D…A)  (Å)  Ligand  Ion  Residues/atoms  Distance(D…A) (Å) 
SAHA  Zn  Asp 178 OD1  2.08  Cmp52  Zn  Asp 178 OD1  2.12 
  Zn  Asp 178 OD2  2.16    Zn  Asp 178 OD2  2.22 
  Zn  His 180  ND1  2.09    Zn  His 180  ND1  2.11 
  Zn  Asp 267 OD2  2.04    Zn  Asp 267 OD2  2.00 
  Zn  Lig O1  2.47    Zn  Tyr 306 OH  2.42 
  Zn  Lig  O2 2.17    Zn  Lig  O2 2.06 
Cmp14  Zn  Asp 178 OD1  2.11  Cmp108  Zn  Asp 178 OD1  2.11 
  Zn  Asp 178 OD2  2.21    Zn  Asp 178 OD2  2.21 
  Zn  His 180  ND1  2.10    Zn  His 180  ND1  2.10 
  Zn  Asp 267 OD2  2.01    Zn  Asp 267 OD2  2.01 
  Zn  Tyr 306 OH  2.37    Zn  Tyr 306 OH  2.30 
  Zn  Lig  O2 2.19    Zn  Lig  O3 2.26 
Cmp17  Zn  Asp 178 OD1  2.10  Cmp118  Zn  Asp 178 OD1  2.08 
  Zn  Asp 178 OD2  2.23    Zn  Asp 178 OD2  2.15 
  Zn  His 180  ND1  2.12    Zn  His 180  ND1  2.09 
  Zn  Asp 267 OD2  2.07    Zn  Asp 267 OD2  2.00 
 Zn  Lig  O2  2.49    Zn  Tyr 306 OH  3.25 
 Zn  Lig  O3  2.19    Zn  Lig O3  2.06 
Cmp22  Zn  Asp 178 OD1  2.15  Cmp119  Zn  Asp 178 OD1  2.08 
 Zn  Asp  178  OD2  2.27    Zn  Asp 178 OD2  2.22 
  Zn  His 180  ND1  2.08    Zn  His 180  ND1  2.06 
  Zn  Asp 267 OD2  2.00    Zn  Asp 267 OD2  2.02 
 Zn  Tyr  306  OH  2.38    Zn  Lig O2  2.17 
 Zn  Lig  O2  2.24    Zn  Lig O3  2.33 
Cmp36  Zn  Asp 178 OD1  2.12         
  Zn  Asp 178 OD2  2.19         
  Zn  His 180  ND1  2.10         
  Zn  Asp 267 OD2  2.01         
 Zn  Tyr  306  OH  2.30         
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Table 4: Interactions, binding free energy and physicochemical properties of docked complexes 
Ligand Hydrophobic 
contact residues 
∆G 
(kcal/
mol) 
MW 
(130 – 725) 
Volume 
(500.0 – 
2000.0) 
donorHB 
(†) 
(0.0 – 6.0) 
accptHB 
(†) 
(2.0 – 
20.0) 
QPlogPo/
w 
(–2.0 – 6.5) 
Rule 
of 
Five 
($) 
SASA 
(300.0 – 
1000.0) 
FOSA 
(0 – 
750) 
FISA 
(7 – 
330) 
Human 
oral 
absorption 
(*) 
PSA 
(7 – 200) 
QPlogPoct 
(8.0 – 35.0) 
QPlogPw 
(4.0 –5.0) 
QPlogS 
(–6.5 – 
0.5) 
QPlogBB 
(–3.0 – 
1.2) 
QPlogKp 
(–8.0 – –
1.0) 
SAHA Gly 151,Phe 207, 
Phe 208 
-42.28  264.32 963.45  3  6.7  0.7  0  583.80  206.13  169.31 3  100.24  18.5  15.3  -1.9  -1.7  -3.0 
Cmp14  His 143,Phe 152, 
Cys 153,Phe 207, 
Phe 208 
-65.40  468.55 1492.74  5  6.7  3.5  0  840.12  210.85  204.20 3  125.96  28.4  20.0  -5.7  -2.4  -2.8 
Cmp17  Gly 151,Phe 152, 
His 180,Met 274 
-45.69  468.55 1440.94  5  6.7  3.2  0  775.38  157.02  203.30 3  121.14  28.6  19.6  -4.7  -2.1  -2.8 
Cmp22  His 143,Gly 151, 
Phe 152,Phe 207, 
Phe 208 
-66.66  468.55 1497.21  5  6.7  3.5  0  846.41  209.56  207.96 3  125.57  28.9  20.4  -5.6  -2.5  -2.8 
Cmp36  His 143,Gly 151, 
Phe 152,Phe 207, 
Phe 208 
-58.63  374.43 1257.28  6  9.7  -0.7  1  731.09  270.24  311.03 1  174.99  27.6  22.5  -1.4  -3.3  -7.5 
Cmp52  His 143,Gly 151, 
Phe 152,Phe 208, 
Met274 
-65.40  379.45 1284.88  4  6.7  2.4  0  746.84  210.16  193.29 3  114.00  24.7  17.9  -4.2  -2.2  -2.9 
Cmp108  His 143,Gly 151, 
Phe 152, Cys153, 
Phe 208, Met274 
-65.98  365.81 1145.38  4  8.7  0.5  0  669.53  206.52  251.48 2  143.69  24.9  18.3  -3.0  -2.5  -4.6 
Cmp118  His 143,Gly 151, 
Phe 152, Cys153, 
Phe 208, Met274, 
Tyr 306 
-54.93  331.37 1108.38  4  8.7  -0.02  0  644.68  215.09  271.02 2  151.76  24.2  18.7  -2.2  -2.8  -4.9 
Cmp119  His 143,Gly 151, 
Phe 152, Cys153, 
Phe 207 
-59.77  331.37 1108.58  4  8.7  0.03  0  651.35  226.79  260.68 2  148.63  23.8  19.1  -2.2  -2.7  -4.7 
∆G Binding free energy calculation. †Estimated number of hydrogen bonds that would be accepted by the solute from water molecules in an aqueous solution. Values are averages taken over a 
number of configurations, so they can be non-integer. $ Number of Lipinski’s rule of five violations. SASA: Total solvent accessible surface area, FOSA: Hydrophobic component of the SASA 
(saturated carbon and attached hydrogen), FISA: Hydrophilic component of the SASA (SASA on N, O, and H on heteroatoms), PSA: Van der Waals surface area of polar nitrogen and oxygen 
atoms. QPlogPoct, QPlogPw, QPlogS and QPlogBB were predicted partition coefficient of octanol/gas, water/gas, aqueous solubility and brain/blood, respectively. QPlogKp was predicted 
skin permeability (log Kp). 
 